{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:54:35Z","timestamp":1793321675128,"version":"4.5.0"},"reference-count":131,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Salud Carlos III, Ministerio de Econom\u00eda y Competitividad","award":["CIBER CB06\/04\/0071"],"award-info":[{"award-number":["CIBER CB06\/04\/0071"]}]},{"name":"Salud Carlos III, Ministerio de Econom\u00eda y Competitividad","award":["EHD19PI03"],"award-info":[{"award-number":["EHD19PI03"]}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["PROMETEO\/2018\/141"],"award-info":[{"award-number":["PROMETEO\/2018\/141"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019157","name":"FISABIO","doi-asserted-by":"publisher","award":["UGP-19-033"],"award-info":[{"award-number":["UGP-19-033"]}],"id":[{"id":"10.13039\/501100019157","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["RTI2018-096748-B-I00"],"award-info":[{"award-number":["RTI2018-096748-B-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["RTI2018-094436-B-I00"],"award-info":[{"award-number":["RTI2018-094436-B-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["FPU18\/02435"],"award-info":[{"award-number":["FPU18\/02435"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["FPU19\/05064"],"award-info":[{"award-number":["FPU19\/05064"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Due to the improved effectiveness and safety of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection has become a manageable, chronic condition rather than a mortal disease. However, HIV patients are at increased risk of experiencing non-AIDS-defining illnesses, with liver-related injury standing out as one of the leading causes of death among these patients. In addition to more HIV-specific processes, such as antiretroviral drug-related toxicity and direct injury to the liver by the virus itself, its pathogenesis is related to conditions that are also common in the general population, such as alcoholic and non-alcoholic fatty liver disease, viral hepatitis, and ageing. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are essential components of combined anti-HIV treatment due to their unique antiviral activity, high specificity, and acceptable toxicity. While first-generation NNRTIs (nevirapine and efavirenz) have been related largely to liver toxicity, those belonging to the second generation (etravirine, rilpivirine and doravirine) seem to be generally safe for the liver. Indeed, there is preclinical evidence of rilpivirine being hepatoprotective in different models of liver injury, independently of the presence of HIV. The present study aims to review the mechanisms by which currently available anti-HIV drugs belonging to the NNRTI family may participate in the development of liver disease.<\/jats:p>","DOI":"10.3390\/cells10071687","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T22:34:36Z","timestamp":1625438076000},"page":"1687","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved"],"prefix":"10.3390","volume":"10","author":[{"given":"Ana M.","family":"Benedicto","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Fuster-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-9513","authenticated-orcid":false,"given":"Joan","family":"Tosca","sequence":"additional","affiliation":[{"name":"Digestive Medicine Department, University Clinical Hospital of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan V.","family":"Esplugues","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain"},{"name":"FISABIO\u2013University Hospital Dr Peset, 46017 Valencia, Spain"},{"name":"Center for Biomedical Research Network\u2013Hepatic and Digestive Diseases (CIBERehd), 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-1470","authenticated-orcid":false,"given":"Ana","family":"Blas-Garc\u00eda","sequence":"additional","affiliation":[{"name":"FISABIO\u2013University Hospital Dr Peset, 46017 Valencia, Spain"},{"name":"Center for Biomedical Research Network\u2013Hepatic and Digestive Diseases (CIBERehd), 46010 Valencia, Spain"},{"name":"Department of Physiology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4487-2471","authenticated-orcid":false,"given":"Nadezda","family":"Apostolova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain"},{"name":"FISABIO\u2013University Hospital Dr Peset, 46017 Valencia, Spain"},{"name":"Center for Biomedical Research Network\u2013Hepatic and Digestive Diseases (CIBERehd), 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11904-016-0332-x","article-title":"Aging of the Liver: What This Means for Patients with HIV","volume":"13","author":"Chan","year":"2016","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e000166","DOI":"10.1136\/bmjgast-2017-000166","article-title":"Mechanisms of liver disease in patients infected with HIV","volume":"4","author":"Kaspar","year":"2017","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): A multicohort collaboration","volume":"384","author":"Smith","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study","volume":"43","author":"Palella","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2010.08.024","article-title":"Liver disease in the HIV-infected individual","volume":"8","author":"Price","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/j.gastro.2009.06.040","article-title":"Coinfection with HIV-1 and HCV\u2014A one-two punch","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.1093\/infdis\/jiaa279","article-title":"Insights into the Pathophysiology of Liver Disease in HCV\/HIV: Does it End with HCV Cure?","volume":"222","author":"Jeyarajan","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/cid\/ciq199","article-title":"HIV mono-infection is associated with FIB-4\u2014A noninvasive index of liver fibrosis\u2014In women","volume":"52","author":"Blackard","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1021\/acs.jmedchem.1c00535","article-title":"Quinolinonyl Non-Diketo Acid Derivatives as Inhibitors of HIV-1 Ribonuclease H and Polymerase Functions of Reverse Transcriptase","volume":"64","author":"Messore","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2174\/1568026619666190712204603","article-title":"Discovery and Development of Anti-HIV Therapeutic Agents: Progress towards Improved HIV Medication","volume":"19","author":"Maeda","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_11","first-page":"1488","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug. Meta. Dispos."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40262-019-00830-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review","volume":"59","author":"Havens","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/hiv.12247","article-title":"Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers","volume":"16","author":"Verloes","year":"2015","journal-title":"HIV Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1128\/AAC.01401-13","article-title":"Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison","volume":"57","author":"Lade","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/00498254.2018.1451667","article-title":"Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans","volume":"49","author":"Sanchez","year":"2019","journal-title":"Xenobiotica"},{"key":"ref_16","unstructured":"LiverTox (2021, March 11). Clinical and Research Information on Drug-Induced Liver Injury, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548290\/."},{"key":"ref_17","unstructured":"LiverTox (2021, March 11). Clinical and Research Information on Drug-Induced Liver Injury, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548514\/."},{"key":"ref_18","unstructured":"LiverTox (2021, March 11). Clinical and Research Information on Drug-Induced Liver Injury, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548267\/."},{"key":"ref_19","unstructured":"LiverTox (2021, March 11). Clinical and Research Information on Drug-Induced Liver Injury, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548241\/."},{"key":"ref_20","first-page":"w13080","article-title":"Liver injury caused by drugs: An update","volume":"140","author":"Stirnimann","year":"2010","journal-title":"Swiss. Med. Wkly."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/acer.12608","article-title":"Effects of Combined Alcohol Anti-HIV Drugs on Cellular Stress Responses in Primary Hepatocytes and Hepatic Stellate and Kupffer Cells","volume":"39","author":"Hu","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bcp.2009.03.022","article-title":"HIV protease inhibitor lopinavir-induced TNF- \u03b1 and IL-6 expression is coupled to the unfoulded protein response and ERK signaling pathways in macrophages","volume":"78","author":"Chen","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3748\/wjg.v19.i1.115","article-title":"Vanishing bile duct syndrome in human immunodeficiency virus infected adults: A report of two cases","volume":"19","author":"Oppenheimer","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/hep.23015","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"50","author":"Puoti","year":"2009","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.23716","article-title":"Clinical syndromes and consequences of antiretroviral-related hepatotoxicity","volume":"52","year":"2010","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Otto, A.O., Rivera, C.G., Zeuli, J.D., and Temesgen, Z. (2021). Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data. Cells, 10.","DOI":"10.3390\/cells10051263"},{"key":"ref_27","first-page":"220","article-title":"HAART and Hepatotoxicity","volume":"7","author":"Ezhilarasan","year":"2017","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00598","DOI":"10.1002\/prp2.598","article-title":"Mechanistic insights into antiretroviral drug-induced liver injury","volume":"8","author":"Pilaye","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.gtc.2017.01.007","article-title":"Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Liver Pathology","volume":"46","author":"Sonderup","year":"2017","journal-title":"Gastroenterol. Clin. North Am."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaci.2015.03.019","article-title":"Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01","volume":"136","author":"Correia","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350901400514","article-title":"Maraviroc: Pharmacokinetics and drug interactions","volume":"14","author":"Abel","year":"2009","journal-title":"Antivir. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/QAI.0b013e3181ee3d82","article-title":"Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2","volume":"55","author":"Hardy","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/AAC.00821-07","article-title":"Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)","volume":"52","author":"Nichols","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s40506-019-00203-7","article-title":"Update on Adverse Effects of HIV Integrase Inhibiotors","volume":"11","author":"Kolakowska","year":"2019","journal-title":"Curr. Treat. Options. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"ref_36","first-page":"52","article-title":"The occurrence of hypersensitivity reaction and hepatotoxicity in individuals receiving integrase strand transfer inhibitors: Results from the EuroSIDA study","volume":"23","author":"Larsen","year":"2020","journal-title":"J. Int. AIDS Soc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0956462417734099","article-title":"Dolutegravir-induced liver injury leading to sub-acute liver failure requiring trasplantation: A case report and review of literature","volume":"29","author":"Wang","year":"2018","journal-title":"Int. J. STD AIDS"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/QAD.0000000000001890","article-title":"Severe cholestatic hepatitis related to abacvir\/lamivudine\/dolutegravir antiretroviral treatment in a HIV-1 infected subject","volume":"32","author":"Rossotti","year":"2018","journal-title":"AIDS"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Neukam, K., Espinosa, N., Collado, A., Delgado-Fern\u00e1ndez, M., Jim\u00e9nez-Aguilar, P., Rivero-Ju\u00e1rez, A., Honta\u00f1\u00f3n-Anto\u00f1ana, V., G\u00f3mez-Berrocal, A., Ruiz-Morales, J., and Merino, D. (2016). Hepatic Safety of Rilpivirine\/Emtricitabine\/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155842"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/hiv.12274","article-title":"Liver toxicity and risk of discontinuation in HIV\/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: Influence of liver fibrosis","volume":"17","author":"Casado","year":"2016","journal-title":"HIV Med."},{"key":"ref_41","unstructured":"Office of AIDS Research (2021, March 08). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/whats-new-guidelines."},{"key":"ref_42","unstructured":"(2021, March 08). European AIDS Clinical Society (EACS) guidelines for the Treatment of Adult HIV-Positive Persons. Available online: https:\/\/www.eacsociety.org\/files\/guidelines-10.1_finaljan2021_1.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1310\/hct1102-110","article-title":"Twelve-year experience of nevirapine use: Benefits and convenience for long-term management in a French cohort of HIV-1-infected patients","volume":"11","author":"Reliquet","year":"2010","journal-title":"HIV. Clin. Trials"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Llibre, J.M., Bravo, I., Ornelas, A., Santos, J.R., Puig, J., Martin-Iguacel, R., Paredes, R., and Clotet, B. (2015). Effectiveness of a treatment switch to Nevirapine plus Tenofovir and Emtricitabine (or lamivudine) in adults with HIV-1 suppressed viremia. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128131"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e4890","DOI":"10.1097\/MD.0000000000004890","article-title":"Long-term efficacy and toxicity of abacavir\/lamivudine\/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide cohort study","volume":"95","author":"Raffi","year":"2016","journal-title":"Medicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00126334-200309011-00005","article-title":"A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients","volume":"34","author":"Stern","year":"2003","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1086\/381450","article-title":"Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors","volume":"38","author":"Dieterich","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1872-034X.2009.00608.x","article-title":"Antiretroviral therapy hepatotoxicity: Prevalence, risk factors, and clinical characteristics in a cohort of Han Chinese","volume":"40","author":"Gao","year":"2010","journal-title":"Hepatol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00126334-200404150-00007","article-title":"Efavirenz versus nevirapine in current clinical practice: A prospective, open-label observational study","volume":"35","author":"Manfredi","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects","volume":"191","author":"Sanne","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/QAD.0b013e32835f1db0","article-title":"Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: A systematic review and meta-analysis","volume":"27","author":"Shubber","year":"2013","journal-title":"AIDS"},{"key":"ref_52","first-page":"139","article-title":"Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine","volume":"15","author":"Casado","year":"2013","journal-title":"AIDS. Rev."},{"key":"ref_53","first-page":"127","article-title":"The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection","volume":"20","author":"Wu","year":"2015","journal-title":"J. Res. Med. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1310\/hct1302-61","article-title":"Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV\/HCV-Coinfected Patients","volume":"13","author":"Neukam","year":"2012","journal-title":"HIV Clin. Trials"},{"key":"ref_55","first-page":"343","article-title":"Hepatotoxicity in patients prescribed efavirenz or nevirapine","volume":"13","author":"Witte","year":"2008","journal-title":"Eur. J. Med Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW","article-title":"Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine","volume":"4","author":"Soriano","year":"2003","journal-title":"HIV. Clin. Trials"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Giacomelli, A., Riva, A., Falvella, F.S., Oreni, M.L., Cattaneo, D., Cheli, S., Renisi, G., Di Cristo, V., Lupo, A., and Clementi, E. (2018). Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3462-5"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00126334-200402010-00003","article-title":"Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals","volume":"35","author":"Patel","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","article-title":"Are adverse events of nevirapine and efavirenz related to plasma concentrations?","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00002030-200201250-00020","article-title":"Liver toxicity caused by nevirapine","volume":"16","author":"Soriano","year":"2002","journal-title":"AIDS"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4102\/sajhivmed.v13i4.116","article-title":"Maternal deaths following nevirapine-based antiretroviral therapy","volume":"13","author":"Bera","year":"2012","journal-title":"S. Afr. J. HIV Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/00126334-200407010-00002","article-title":"Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022","volume":"36","author":"Hitti","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3844\/ajptsp.2013.20.30","article-title":"Concentration-Effect, Incidence and Mechanism of Nevirapine Hepatotoxicity","volume":"8","author":"Elias","year":"2013","journal-title":"Am. J. Pharmacol. Toxicol."},{"key":"ref_64","first-page":"38","article-title":"A Structured Review of Hepatotoxic Medicines during Pregnancy","volume":"32","author":"Cano","year":"2017","journal-title":"Rev. Col. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00002030-200403260-00007","article-title":"Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: Harmful impact of nevirapine","volume":"18","author":"Castellano","year":"2004","journal-title":"AIDS"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1086\/524080","article-title":"Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection","volume":"46","author":"Berenguer","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3851\/IMP2703","article-title":"Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon\/ribavirin therapy","volume":"19","author":"Barreiro","year":"2014","journal-title":"Antivir. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/tx034064+","article-title":"Characterization of a potential animal model of an idiosyncratic drug reaction: Nevirapine-induced skin rash in the rat","volume":"16","author":"Shenton","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"ref_69","first-page":"932542","article-title":"The role of the immune system in Nevirapine-induced subclinical liver injury of a rat model","volume":"2012","author":"Bekker","year":"2012","journal-title":"ISRN Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1021\/tx300172s","article-title":"Bioactivation of Nevirapine to a Reactive Quinone Methide: Implications for Liver Injury","volume":"25","author":"Sharma","year":"2012","journal-title":"Chem. Res. Toxicol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1021\/tx400232s","article-title":"Identification of danger signals in nevirapine-induced skin rash","volume":"26","author":"Zhang","year":"2013","journal-title":"Chem. Res. Toxicol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1172\/JCI127502","article-title":"Parental metabolic syndrome epigenetically reprograms offspring hepatic lipid metabolism in mice","volume":"130","author":"Orime","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/01913123.2017.1422831","article-title":"Nevirapine-induced liver lipid-SER inclusions and other ultrastructural aberrations","volume":"42","author":"Sastry","year":"2018","journal-title":"Ultrastruct. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1021\/acs.chemrestox.5b00305","article-title":"The Combination of Anti-CTLA-4 and PD1-\/-Mice Unmasks the Potential of Isoniazid and Nevirapine to Cause Liver Injury","volume":"28","author":"Mak","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2131\/jts.38.741","article-title":"Differential responses of human hepatocytes to the non-nucleoside HIV-1 reverse transcriptase inhibitor nevirapine","volume":"38","author":"Fang","year":"2013","journal-title":"J. Toxicol. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.apjtm.2016.04.015","article-title":"Nevirapine induces apoptosis in liver (HepG2) cells","volume":"9","author":"Wongtrakul","year":"2016","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"9194","DOI":"10.1038\/s41598-017-09321-y","article-title":"Nevirapine induced mitochondrial dysfunction in HepG2 cells","volume":"7","author":"Paemanee","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1021\/acs.jmedchem.9b01990","article-title":"Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death","volume":"63","author":"Heck","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hep.23647","article-title":"Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells","volume":"52","author":"Apostolova","year":"2010","journal-title":"Hepatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cbi.2015.11.023","article-title":"Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes","volume":"255","author":"Terelius","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.106.112136","article-title":"Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers","volume":"320","author":"Faucette","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bcp.2013.04.002","article-title":"Agonism of human pregnane X receptor by rilpivirine and etravirine: Comparison with first generation non-nucleoside reverse transcriptase inhibitors","volume":"85","author":"Sharma","year":"2013","journal-title":"Biochem Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/bph.12997","article-title":"Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine","volume":"172","author":"Sharma","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/acs.chemrestox.7b00065","article-title":"Supernatant from Hepatocyte Cultures with Drugs That Cause Idiosyncratic Liver Injury Activates Macrophage Inflammasomes","volume":"30","author":"Kato","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jac\/dkl524","article-title":"Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors","volume":"59","author":"Rivero","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/jac\/dkr357","article-title":"Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV\/hepatitis C virus co-infected patients","volume":"77","author":"Neukam","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jinf.2005.05.020","article-title":"Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure","volume":"52","year":"2006","journal-title":"J. Infect."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1086\/313629","article-title":"Hypersensitivity syndrome associated with efavirenz therapy","volume":"30","author":"Bossi","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2125.2008.03238.x","article-title":"Efavirenz concentrations in HIV-infected patients with and without viral hepatitis","volume":"66","author":"Pereira","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1124\/jpet.106.102657","article-title":"Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes","volume":"318","author":"McRae","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/cid\/cix467","article-title":"Changes in liver steatosis after switching from Efavirenz to Raltegravir among Human Immunodeficiency Virus-infected patients with Nonalcoholic Fatty Liver Disease","volume":"65","author":"Mancebo","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2018.12.038","article-title":"Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis","volume":"70","author":"Gwag","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/j.1476-5381.2010.00866.x","article-title":"Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells","volume":"160","author":"Apostolova","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.taap.2011.09.008","article-title":"Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes","volume":"257","author":"Bumpus","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.redox.2015.01.005","article-title":"Mechanisms of cell death pathway activation following drug-induced inhibition of mitochondrial complex I","volume":"4","author":"Imaizumi","year":"2015","journal-title":"Redox Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10565-016-9362-9","article-title":"Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity","volume":"33","author":"Ganta","year":"2017","journal-title":"Cell Biol. Toxicol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/1087057114557621","article-title":"The acute extracellular flux (XF) assay to assess compound effects on mitochondrial function","volume":"20","author":"Wang","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jhep.2013.06.005","article-title":"ER stress in human hepatic cells treated with Efavirenz: Mitochondria again","volume":"59","author":"Apostolova","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1124\/mol.118.113647","article-title":"Efavirenz and Efavirenz-like Compounds Activate Human, Murine, and Macaque Hepatic IRE1\u03b1-XBP1","volume":"95","author":"Heck","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hep.24459","article-title":"Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy","volume":"54","author":"Apostolova","year":"2011","journal-title":"Hepatology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/0091270004269142","article-title":"Induction of CYP3A4 by efavirenz in primary human hepatocytes: Comparison with rifampin and phenobarbital","volume":"44","author":"Hariparsad","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1172\/JCI128274","article-title":"Pregnane X receptor activation potentiates ritonavir hepatotoxicity","volume":"129","author":"Shehu","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/jcph.245","article-title":"Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial","volume":"54","author":"Kakuda","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3851\/IMP1662","article-title":"Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials","volume":"15","author":"Katlama","year":"2010","journal-title":"Antivir. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1097\/QAD.0000000000000425","article-title":"Etravirine-based antiretroviral therapy in HIV\/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir","volume":"28","author":"Ramirez","year":"2014","journal-title":"AIDS"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1468-1293.2012.00994.x","article-title":"Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: Further analysis of adverse events and laboratory abnormalities of special interest","volume":"13","author":"Girard","year":"2012","journal-title":"HIV Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/jac\/dkr533","article-title":"Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial","volume":"67","author":"Fatkenheuer","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/jac\/dks130","article-title":"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus co-infection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials","volume":"67","author":"Nelson","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"20037","DOI":"10.7448\/IAS.18.1.20037","article-title":"Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy","volume":"18","author":"Gianotti","year":"2015","journal-title":"J. Int. AIDS. Soc."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/IDR.S152090","article-title":"Durability, safety, and efficacy of rilpivirine in clinical practice: Results from the SCOLTA Project","volume":"11","author":"Bagella","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jac\/dks400","article-title":"Rare case of rilpivirine-induced severe allergic hepatitis","volume":"68","author":"Ahmed","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/sextrans-2019-054336","article-title":"A case of rilpivirine drug-induced liver injury","volume":"96","author":"Lee","year":"2020","journal-title":"Sex. Transm. Infect."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults","volume":"28","author":"Cohen","year":"2014","journal-title":"AIDS"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/ciu234","article-title":"Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-infected adults treated with rilpivirine or efavirenz for 96 weeks in the ECHO and THRIVE trials","volume":"59","author":"Tebas","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/15284336.2015.1112480","article-title":"Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia","volume":"17","author":"Thamrongwonglert","year":"2016","journal-title":"HIV Clin. Trials"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Taramasso, L., Tatarelli, P., Ricci, E., Madeddu, G., Menzaghi, B., Squillace, N., De Socio, G.V., Martinelli, C., Gulminetti, R., and Maggi, P. (2018). Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA). BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3268-5"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Curran, A., Rull, A., Navarro, J., Vidal-Gonz\u00e1lez, J., Martin-Castillo, M., Burgos, J., Falc\u00f3, V., Ribera, E., Torrella, A., and Planas, B. (2020). Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV\/FTC\/TDF to RPV\/FTC\/TDF: A Randomized Open-Label Trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051246"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1093\/jac\/dku262","article-title":"Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: A comparison with efavirenz","volume":"69","author":"Polo","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_120","first-page":"929","article-title":"Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells","volume":"69","author":"Alegre","year":"2020","journal-title":"Gut"},{"key":"ref_121","first-page":"201","article-title":"Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data","volume":"12","author":"Rock","year":"2020","journal-title":"HIV AIDS"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus\u20131 infection: Week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"DRIVE-FORWARD trial group. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1060028019869641","article-title":"Doravirine: A Return of the NNRTI Class?","volume":"54","author":"Blevins","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/COH.0000000000000471","article-title":"Doravirine: A review","volume":"13","author":"Colombier","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1128\/AAC.02650-15","article-title":"Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jac\/dkaa401","article-title":"In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations","volume":"76","author":"Saladini","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e02016","DOI":"10.1128\/AAC.02016-18","article-title":"Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions","volume":"63","author":"Khalilieh","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e02492","DOI":"10.1128\/AAC.02492-18","article-title":"In Vitro Evaluation of the Drug Interaction Potential of Doravirine","volume":"63","author":"Bleasby","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/jcph.857","article-title":"Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics","volume":"57","author":"Khalilieh","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/QAD.0000000000002725","article-title":"Changes in weight and BMI with first-line doravirine-based therapy","volume":"35","author":"Orkin","year":"2021","journal-title":"AIDS"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/7\/1687\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:25:44Z","timestamp":1760163944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/7\/1687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,4]]},"references-count":131,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["cells10071687"],"URL":"https:\/\/doi.org\/10.3390\/cells10071687","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,4]]}}}